| Honorific Prefix: | Sir |
| Tony Kouzarides | |
| Birth Date: | 1958 1, df=yes[1] |
| Fields: | Cancer Chromatin Transcription |
| Workplaces: | University of Leeds University of Cambridge Gurdon Institute New York University Laboratory of Molecular Biology Abcam |
| Alma Mater: | University of Leeds (BSc) University of Cambridge (PhD) |
| Thesis Title: | A molecular analysis of transformation by human cytomegalovirus |
| Thesis Url: | http://ulmss-newton.lib.cam.ac.uk/vwebv/holdingsInfo?bibId=10515 |
| Thesis Year: | 1985 |
| Doctoral Advisor: | Tony Minson[2] |
| Awards: | Heinrich Wieland Prize Fellow of the Royal Society (2012) FMedSci (2001)[3] |
| Website: | |
Sir Tony Kouzarides, FMedSci,[3] FRS[4] (born 17 January 1958) is a senior group leader Gurdon Institute,[5] a founding non-executive director of Abcam[6] and a Professor of Cancer Biology at the University of Cambridge.[7]
Tony did his PhD at the University of Cambridge and postdoctoral work at MRC Laboratory of Molecular Biology in Cambridge and New York University Medical Center. His research group at the Gurdon Institute is focused on epigenetic modifications and their involvement in cancer.
Tony Kouzarides is Professor of Cancer Biology at the University of Cambridge and a group leader at the Gurdon Institute. He currently holds the following directorships: Director and Co-founder of the Milner Therapeutics Institute, director of Cambridge Gravity and director of STORM Therapeutics.
Tony is founder/director of Cambridge Gravity, an organization for the promotion of science at the University of Cambridge. He is founder, patron and ex-director of a cancer charity in Spain called Conquer Cancer (Vencer el Cancer). He is on the Scientific Advisory Board of the Institute of Cancer Research (UK) and on the Executive Board of the CRUK Cambridge Cancer Centre.
Tony is a co-founder and ex-director of Abcam plc, a publicly trading research reagents company in Cambridge, a co-founder and ex-director of Chroma Therapeutics, of a drug discovery company based in Oxford and a co-founder and current director of STORM Therapeutics, a drug discovery company based in Cambridge.
Kouzarides has been elected member of the European Molecular Biology Organization, Fellow of the British Academy of Medical Sciences (FMedSci), Fellow of the Royal Society (FRS), Fellow of the American Academy of Arts and Sciences (AAAS) and is a Cancer Research UK Gibb Fellow. He has been awarded the Wellcome Trust medal for research in biochemistry related to medicine (UK), the Tenovus Medal (UK), the Bodossaki Foundation prize in Biology (Greece), the Bijvoet Medal (Holland), the Biochemical Society Award Novartis Medal and Prize (UK) and the Heinrich Wieland Prize (Germany).
He was knighted in the 2024 King's Birthday Honours "for services to healthcare innovation and delivery".